Methadone in Post-Herpetic Neuralgia Pain (NPH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01752699|
Recruitment Status : Completed
First Posted : December 19, 2012
Last Update Posted : March 18, 2013
University of Sao Paulo
Information provided by (Responsible Party):
Daniel Ciampi Araujo de Andrade, University of Sao Paulo
Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.
|Condition or disease||Intervention/treatment||Phase|
|Post-herpetic Neuralgia||Drug: Methadone Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Methadone in Post-Herpetic Neuralgia Pain|
|Study Start Date :||January 1998|
|Actual Primary Completion Date :||February 2013|
|Actual Study Completion Date :||March 2013|
in this arm patients will take methadone 5mg.
patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
in this arm patients will take placebo pills.
patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
Primary Outcome Measures :
- Change in baseline Pain [ Time Frame: baseline (visit inclusion) and three moths latter ]Assessing by verbal analog scale (VAS)
No Contacts or Locations Provided